No pharmacologic treatment has been developed to target the pathogenic disturbances observed in skeletal muscle (muscle insulin resistance), although it is responsible for most of the glucose uptake of the entire body under insulin stimulation (Stump et al., 2006; Gogoi et al., 2014), and it is considered to be the hallmark of T2D (Lillioja et al., 1988; Shepherd and Kahn, 1999; DeFronzo, 2004). The gene discussed is INS; the disease is Insulin resistance.